• Skip to content
  • Skip to navigation
  • Skip to footer
AstraZeneca logo AstraZeneca logo
AstraZeneca logo AstraZeneca logo
  • AstraZeneca Websites
  • Global site
  • What science can do
    What science can do
    • Stories of impact
    • Publications
  • R&D
    R&D
    • Our approach
      Our approach to R&D
      • STEM at AstraZeneca
    • Precision medicine
    • Transformative science
    • Data science & AI
    • Clinical innovation
    • Our technologies
    • Next generation therapeutics
    • R&D strategic centres
    Featured website AstraZeneca Clinical Trials Clinical trial website thumbnail Featured website Open Innovation OpenInnovation logo
  • Our therapy areas
    Our therapy areas
    • Oncology
    • BioPharmaceuticals
    • Cardiovascular, Renal and Metabolism
    • Respiratory & Immunology
    • Vaccines and Immune Therapies
    • Rare Disease
    • Pipeline
    • All medicines
  • Our company
    Our company
    • Our history
    • Our people
      Our people
      • Oncology
      • BioPharmaceuticals
      • Rare Disease
      • Research & Development
      • Enabling functions
      • Operations
      • International
    • Our leadership
    • Cambridge
    • Gothenburg
    • Gaithersburg
  • Careers
    Careers
    • Great place to work
    • Inclusion and diversity
    • Learning and development
    • Employee resource groups
  • Investors
    Investor Relations (Global)
    • Investor Relations (Sweden)
    • Resources
    • Governance
    • Shareholder information
    • Dividend policy
    • Key facts
    • FAQs
    • Debt Investors
    • ADR Programme
    Feature Results and presentations ipad image
  • Media
    Media
    • Press Releases
    • Articles
    • Image library
    • Archive
    • Media contacts
    • Investor Day 2024
  • Sustainability
    Sustainability
    • Climate change
      Climate change overview
      • Renewables
      • Product sustainability
      • AZ Forest
    • Nature
      Nature overview
      • Water stewardship
      • Pharmaceuticals in the environment
      • Waste and circularity
    • Health equity
      Health equity overview
      • Science
      • Healthcare delivery
      • Community investment
    • Health systems resilience
      Health systems resilience overview
      • Partnership for Health System Sustainability and Resilience (PHSSR)
    • Ethics and governance
      Ethics and Compliance
      • Governance
      • Sustainability governance
    • Our people
      Great place to work
      • Inclusion and diversity
      • Learning and development
      • Workforce safety and health
    • Our Values
    • Partnerships and alliances
    • Resources
      Sustainability resources
      • Our sustainability impact
    Feature Our sustainability impact Feature Sustainable science
  • Partnering
    Partnering
    • Our business development teams
    • Our areas of partnering interest
    • Why partner with AstraZeneca?
    • Information for Suppliers
    • Supplier Sustainability Hub
    • Sustainable procurement
    • A Catalyst Network

Results 21 – 30 of 231 for second dose AstraZeneca (0.05 seconds)

AstraZeneca announces positive Phase III top-line results for PT003 from PINNACLE 1 and PINNACLE 2 studies in COPD

AstraZeneca announces positive Phase III top-line results for PT003 from PINNACLE 1 and PINNACLE 2 studies in COPD

18 March 2015

การศึกษาการใช้จริงในประเทศไทย เผยว่า วัคซีนป้องกันโควิด-19 ของแอสตร้าเซนเนก้า มีประสิทธิผลในการป้องกันการติดเชื้อจากสายพันธุ์โอมิครอนสูงถึง 73% หลังการฉีดเป็นวัคซีนเข็มกระตุ้นที่สี่

จากแอสตร้าเซนเนก้า สำหรับข้อมูลเพิ่มเติมกรุณาไปยังเว็บไซต์ astrazeneca.com และช่องทางทวิตเตอร์ @AstraZeneca สำหรับข้อมูลเพิ่มเติมเพื่อบุคลากรทางการแพทย์ และ ...

19 July 2022

AstraZeneca delivers 5.3 million doses of COVID-19 vaccine to Thailand during July

AstraZeneca delivers 5.3 million doses of COVID-19 vaccine to Thailand during July

3 August 2021

AstraZeneca updates on olaparib and TC-5214 development programmes

AstraZeneca updates on olaparib and TC-5214 development programmes

20 December 2011

วัคซีนป้องกันโควิด-19 ของแอสตร้าเซนเนก้า ได้รับการอนุมัติ ให้ใช้เป็นวัคซีนกระตุ้นเข็มที่สามในสหภาพยุโรป

จากแอสตร้าเซนเนก้า สำหรับข้อมูลเพิ่มเติมกรุณาไปยังเว็บไซต์ astrazeneca.com และช่องทางทวิตเตอร์ @AstraZeneca

23 May 2022

Brilique (ticagrelor) approved in EU for extended treatment of patients with history of heart attack

Approval of new 60mg dose expands current indication to include long-term treatment beyond the first year 19 February 2016 AstraZeneca today announced ...

19 February 2016

Beyfortus approved in the US for the prevention of RSV lower respiratory tract disease in infants

RSV season Across all clinical endpoints, a single dose of Beyfortus delivered consistent and sustained efficacy against RSV disease vs placebo ...

17 July 2023

AstraZeneca announces top-line results of OSKIRA-4 Phase IIb study of fostamatinib as a monotherapy for rheumatoid arthritis

AstraZeneca announces top-line results of OSKIRA-4 Phase IIb study of fostamatinib as a monotherapy for rheumatoid arthritis

13 December 2012

การศึกษาล่าสุดเผย วัคซีนป้องกันโควิด-19 ของแอสตร้าเซนเนก้า และวัคซีน mRNA มีประสิทธิผลในการป้องกันการเข้ารักษาตัวในโรงพยาบาล และการเสียชีวิตจากโควิด-19 ได้ในระดับสูงไม่แตกต่างกัน

จากแอสตร้าเซนเนก้า สำหรับข้อมูลเพิ่มเติมกรุณาไปยังเว็บไซต์ astrazeneca.com และช่องทางทวิตเตอร์ @AstraZeneca สำหรับข้อมูลเพิ่มเติมเพื่อบุคลากรทางการแพทย์ และ ...

14 July 2022

Bevespi Aerosphere™ approved by the US FDA for patients with COPD

bronchodilator delivered through a pressurised metered-dose inhaler (pMDI) and first product to use AstraZeneca’s patented Co-SuspensionTM Technology ...

25 April 2016

Previous 1 2 3 4 5 6 7 8 9 10 11 12 Next

AstraZeneca Websites

This website is intended for people seeking information on AstraZeneca's worldwide business. Our country sites can be located in the AZ Network.


Veeva ID: Z4-68564
Date of next review: August 2026

Resources

  • All resources
  • Open Innovation
  • Externally sponsored scientific research
  • Medical Information for HCPs
  • US prescription assistance programmes
  • Global clinical trials information
  • Medicines
  • Report a possible side effect

Quick links

  • Media
  • Investor Relations
  • Partnering
  • Careers
  • Sustainability
  • Modern Slavery Statement
  • AZethics – Report A Concern
  • Supplier information
  • Social Media Community Guidelines

Social Media

  • Linkedn
  • Instagram
  • Facebook
  • Twitter
  • YouTube
  • Glassdoor

utility links

  • Legal notice and Terms of Use
  • Privacy notice
  • Site map
  • Contact us
  • Cookie preferences

© AstraZeneca 2025

You are now leaving AstraZeneca.com

You have selected a link that will take you to a site maintained by a third party who is solely responsible for its contents.

AstraZeneca provides this link as a service to website visitors. AstraZeneca is not responsible for the privacy policy of any third party websites. We encourage you to read the privacy policy of every website you visit.

Click ‘cancel’ to return to AstraZeneca’s site or ‘continue’ to proceed.

Cancel Continue

Important notice for users

You are about to access AstraZeneca historic archive material. Any reference in these archives to AstraZeneca products or their uses may not reflect current medical knowledge and should not be used as a source of information on the present product label, efficacy data or safety data. Please refer to your approved national product label (SmPC) for current product information.

I have read this warning and will not be using any of the contained product information for clinical purposes.

I disagree I agree